Plain-English translation of NCT07435779 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing autologous CAR-T cell therapy as a potential new treatment for ulcerative colitis — a serious digestive condition causing severe inflammation of the colon. The treatment uses your own immune cells, which are collected, modified in a lab to better target the disease, and then infused back into your body. Researchers want to see if this approach can help people whose colitis has not improved with existing medications.
Many people with ulcerative colitis don't respond well enough to standard drugs and biologics, leaving them with ongoing pain, bleeding, and damaged intestines. This trial exists to explore whether retraining the immune system through this new therapy might offer hope for patients who have exhausted other treatment options.
You likely qualify if…
You likely don't qualify if…
Your participation would involve several steps: first, your own immune cells will be collected through a special blood procedure. These cells are then sent to a laboratory where they are modified to better fight your disease. After about 2–4 weeks, the modified cells are infused back into your body as an infusion. You will be monitored closely at 12 weeks and again at 52 weeks to see if your symptoms improve, including through endoscopy (a scope exam of your colon), imaging, and blood work. The study runs for about one year total, with regular visits to check your health and watch for any side effects.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Hebei Senlang Biotechnology Inc., Ltd.
Enrollment target
~12 participants
Started
February 2026
Primary completion
February 2027
Age range
18 Years – 60 Years
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yingdi Chen
Foresea Life Insurance Guangzhou General Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.